GTC Biotherapeutics to Webcast Corporate Presentation at BIO CEO & Investor Conference 2007.FRAMINGHAM, Mass. -- GTC GTC See: Good 'til cancelled order GTC See good-till-canceled order (GTC). Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB GTCB Gulf Tax Credit Bond (Alabama, Louisiana, Mississippi, USA) ), announced today that Geoffrey Cox (Charles) Geoffrey Cox, QC (born April 30, 1960) is a British Conservative politician and barrister. He is the Member of Parliament for Torridge and West Devon. Geoffrey Cox was educated at King's College, Taunton and Downing College, Cambridge. , Ph.D., GTC's Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , is scheduled to present on Monday, February 12, 2007 at 12:30 p.m. Eastern Time during the BIO CEO & Investor Conference 2007. The conference is being held at the Waldorf Astoria, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , New York from February 12-14, 2007. The presentation will be webcast live and can be accessed by logging onto www.gtc-bio.com. Replays can be accessed from this same website and will be available within 24 hours of the presentation. GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal Transgenic animal Animals that have had genes from other species inserted into their genetic code. Mentioned in: Glycogen Storage Diseases technology. In August 2006, ATryn([R]), GTC's recombinant form of human antithrombin, was approved by the European Commission for use in patients with hereditary antithrombin deficiency undergoing surgical procedures. This was the first approval anywhere in the world of a therapeutic protein produced from a transgenic animal. ATryn([R]) is in phase III studies to support a filing in the United States requesting approval in the hereditary deficiency indication. In addition, GTC established a strategic collaboration with LFB LFB Legislative Fiscal Bureau LFB London Fire Brigade LFB Linear Frame Buffer LFB Left Fullback (soccer) LFB Lyman Frank Baum (The Wizard of Oz author) LFB Liquid Factor Boiling LFB Low-Frequency Beacon Biotechnologies of France to jointly develop recombinant forms of human plasma proteins and monoclonal antibodies. The first program of the collaboration will be to develop recombinant human factor VIIa as a potential treatment for hemophilia in patients with antibodies to other coagulation factors. GTC has also recently been granted a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC's transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as those that are required in large volumes. Additional information is available on the GTC web site, http://www.gtc-bio.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion